Ignite Creation Date:
2024-05-06 @ 2:29 AM
Last Modification Date:
2024-10-26 @ 11:19 AM
Study NCT ID:
NCT02052635
Status:
TERMINATED
Last Update Posted:
2016-05-27
First Post:
2014-01-14
Brief Title:
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase IV Randomised Multi-Centre Open Label Study Comparing Ticagrelor Versus Clopidogrel in Non-ST Elevation Acute Coronary Syndrome NSTE-ACS Patients Undergoing Percutaneous Coronary Intervention PCI With Bivalirudin
Status:
TERMINATED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Patient recruitment challenges low enrolment and a forecasted inability to complete the study in an acceptable timeframe
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NSTE-ACS
Brief Summary:
The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome NSTE-ACS undergoing ad hoc percutaneous coronary intervention PCI with bivalirudin
Detailed Description:
Multi-center open-label study that will compare the onset of the platelet inhibition with ticagrelor versus clopidogrel when administered with bivalirudin during PCI on a background therapy of aspirin in patients with NSTE-ACS
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None